A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

Genentech, Inc.92 enrolled

Overview

This randomized, open-label, 4-arm, multiple-dose study will evaluate the effect of coadministration of a protein pump inhibitor, an inhibitor of P-glycoprotein and CYP3A4, or an inhibitor of CYP2C9 on the pharmacokinetics of vismodegib in healthy female subjects of non-childbearing potential. Subjects will be randomized to receive multiple oral doses of vismodegib, alone or in combination with multiple oral doses of either rabeprazole, itraconazole or fluconazole. Anticipated time on study treatment is up to 11 days.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

NONE

Enrollment

Conditions

Healthy Volunteer

Interventions

fluconazoleDRUG

Multiple oral doses

itraconazoleDRUG

Multiple oral doses

rabeprazoleDRUG

Multiple oral doses

vismodegib

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Females of non-childbearing potential * Body mass index (BMI) 18 to 32 kg/m2, inclusive * In good health, determined by no clinically significant findings from medical history, physical examination. 12-lead ECG, and vital signs * Clinical laboratory evaluations, complete blood count and urinalysis within the normal range for the test laboratory, unless not deemed clinically significant by the investigator * Negative test for drugs of abuse at screening and check-in (including alcohol) * Negative for hepatitis B, hepatitis C and HIV infection * Non-childbearing potential is defined as: non-pregnant, non-lactating, and either postmenopausal for at least 1 year or surgically sterile (e.g. bilateral oophorectomy and/or hysterectomy) Exclusion Criteria: * Significant history or clinical evidence of any metabolic (including type 1 or 2 diabetes). allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, endocrine, GI (including gastric or duodenal ulcers), Zollinger-Ellison syndrome, Barrett's esophagus, urological, neurological, or psychiatric disorder * History of inflammatory arthritis * History of symptomatic hypotension * History of seizure disorders * History of bipolar or major depressive disorder * History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy will be allowed) * History of alcoholism or drug addiction within 1 year prior to check-in * Use of any tobacco- or nicotine-containing products within 6 months prior to check-in * Participation in any other investigational study drug or biological agent trial in which receipt of investigational study drug occurred within 5 half-lives or 30 days, whichever is longer, prior to check-in * Use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to check-in * History of chronic PPI use (\> 30 days of continuous daily dosing) within 6 months of check-in

Locations (2)

Unnamed facility

Daytona Beach, Florida, United States

Unnamed facility

Dallas, Texas, United States

Outcomes

Primary Outcomes

Relative effect of rabeprazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)

Time frame: up to 12 days

Relative effect of itraconazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)

Time frame: up to 12 days

Relative effect of fluconazole on the steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css)

Time frame: up to 12 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.